LOS ANGELES (MarketWatch) -- Japanese stocks rose in early Monday trading, with weaker-than-expected trade data pushing the yen lower, which in turn helped some export stocks. The Nikkei Stock Average (JP:NIK) added 1% to 14,704.36, with the broader Topix up 0.8%, also enjoying support from gains Friday in the U.S. After data showing exports grew less than analysts had projected, the dollar (USDJPY) moved back above the 98-yen level, sending some exporters climbing, with a 2.2% rise for Fujitsu Ltd. (JP:6702) (FJTSY) , a 1.2% improvement for Alps Electric Co. (JP:6770) , and a 1% bump for Toyota Motor Corp. (JP:7203) (TM) . Shares of Suzuki Motor Corp. (JP:7269) (SZKMF) added 2.9% after a Nikkei report saying the company would record its highest-ever operating profit for the April-September half. Retailers were also a strong spot Monday, with J. Front Retailing Co. (JP:3086) up 2%, online marketplace Rakuten Inc. (JP:4755) (RKUNF) adding 2.4%, and 7-Eleven operator Seven & I Holdings Co. (JP:3382) (SVNDF) ahead by 1.4%.
10 Best Stocks To Buy For 2015: Greenhill & Co Inc (GHL)
Greenhill & Co., Inc. (Greenhill), incorporated on March 10, 2004, is an independent investment bank focused on providing financial advice on mergers, acquisitions, restructurings, financings and capital raising to corporations, partnerships, institutions and governments. The Company acts for clients located throughout the world from its offices in the United States, United Kingdom, Germany, Canada, Japan, Australia and Sweden. The Company provides advisory services primarily in connection with mergers and acquisitions, financings, restructurings, and capital raisings. On merger and acquisition engagements, it provide a broad range of advice to global clients in relation to domestic and cross-border mergers, acquisitions, and similar corporate finance matters and are generally involved at each stage of these transactions, from initial structuring to final execution. It advises client�� matters, including acquisitions, divestitures, defensive tactics, special committee projects and other important corporate events. It also provides advice on valuation, tactics, industry dynamics, structuring alternatives, timing and pricing of transactions, and financing alternatives.
In the Company�� financing advisory and restructuring practice, the Company advise debtors, creditors, governments, other stakeholders and companies experiencing financial distress as well as potential acquirers of distressed companies and assets. It provides advice on valuation, restructuring alternatives, capital structures, financing alternatives, and sales or recapitalizations. The Company also assists those clients who seek court-assisted reorganizations by developing and seeking approval for plans of reorganization as well as the implementation of such plans. In its private capital and real estate capital advisory business the Company assists fund managers and sponsors in raising capital for new funds and provide related advisory services to private equity and real estate funds and other organizations globally. It ! also advises on secondary transactions.
The Company competes with America Corporation, Barclays Bank PLC, Citigroup Inc., Credit Suisse, Deutsche Bank AG, Goldman Sachs Group, Inc., JPMorgan Chase & Co., Morgan Stanley, UBS A.G., Evercore Partners Inc., Jefferies Group, Inc., Lazard Ltd., Credit Suisse and Park Hill.
Advisors' Opinion:- [By Matt Koppenheffer and David Hanson]
An article in Financial Times came out suggesting that smaller investment banks, such as Greenhill (NYSE: GHL ) or Lazard (NYSE: LAZ ) , might be workplaces that offer more options and flexibility for those pursuing a banking career. Will we start to see the best talent move away from Wall Street's biggest banks to find the true opportunities? In the video, Matt tells us what effect this could have on big banking as a whole.
- [By John Seward]
Timken Steel Corp. will replace Greenhill & Co. (NYSE: GHL), and Greenhill replaces Spartan Motors Inc. (NASDAQ: SPAR) in the SmallCap 600 June 30. Timken Co. (NYSE: TKR) is spinning off TimkenSteel to shareholders.
- [By Mark Hulbert]
The stocks are C.H. Robinson Worldwide (CHRW) �, a freight-transportation company; chip maker Cirrus Logic (CRUS) �; independent oil company Forest Oil (FST) �; investment bank Greenhill & Co. (GHL) �; Intrepid Potash (IPI) �, a fertilizer company; retailer J.C. Penney (JCP) �; Quest Diagnostics (DGX) �, a medical diagnostic company; Strayer Education (STRA) �, a for-profit college; Tower Group International (TWGP) �, an insurance company; and Windstream Holdings (WIN) �, a rural telecommunications firm.
Best Japanese Stocks To Invest In Right Now: Zulily Inc (ZU)
Zulily, Inc., incorporated on October 16, 2009, is an e-commerce company. The Company, through its desktop and mobile Websites and mobile applications, which it refers to as its sites, helps its customers discover new and unique products. The Company provides moms with a selection of over 4,500 product styles offered on a typical day through various flash sales events, which are limited-time curated online sales of selected products launched each day on its sites. The Company offers merchandise primarily targeted at moms purchasing for their children, themselves and their homes. Its merchandise includes children�� apparel, women�� apparel, and other product categories, such as toys, infant gear, kitchen accessories and home decor The Company sources its merchandise from thousands of vendors, including emerging brands and smaller boutique vendors, as well as larger national brands.The Company offers merchandise primarily targeted at moms purchasing for their children, themselves and their homes. Its merchandise includes children�� apparel, women�� apparel, and other product categories such as toys, infant gear, kitchen accessories and home decor.
Offering for Moms
The Company launches a variety of flash sales event. Typically, these events feature over 4,500 product styles from different vendors and last for 72 hours. The day�� events are kicked off by an early morning e-mail to its email subscribers and push communication to users of its mobile applications offerings are only available for a limited time and in a limited quantity.
Offering for Vendors
The Company�� primary vendors are emerging brands and smaller boutique vendors. These are typically small-to-medium sized businesses, many of which were started by mom entrepreneurs. The Company introduces these vendors to its large audience and help them tell their stories in a way that differentiates their products and properly reflects their brand attributes. Its entire operational infr! astructure-photography studios, editorial writers, fulfillment operations and technology capabilities-is designed to showcase these emerging brands��and smaller boutique vendors��products in the most compelling, engaging and personalized way.
The Company competes with Amazon.com, Target, Toys R Us, Walmart and eBay.
Advisors' Opinion:- [By Dan Caplinger]
Wednesday proved to be another example of the resiliency of the bull market in stocks, as major market benchmarks bounced back from yesterday's losses to regain a substantial chunk of their lost ground. Even though U.S. GDP figures for the first quarter got revised downward to an ugly drop of 2.9%, few investors believe that the decline is anything but a one-time seasonal aberration. Helping to lead the market higher today were stocks from a number of different industries, including Penn Virginia (NYSE: PVA ) , Hanesbrands (NYSE: HBI ) , and zulily (NASDAQ: ZU ) .
- [By Rex Crum]
Other Internet-based stocks rose in the wake of the Priceline-OpenTable deal, with Yelp Inc. (YELP) �up almost 14%, Groupon Inc. (GRPN) �rising nearly 4% and online falsh-deal company Zulily Inc. (ZU) �up by 5%.
- [By Rick Aristotle Munarriz]
David Paul Morris/Bloomberg via Getty Images Companies can make brilliant moves, but there are also times when things don't work out quite as planned. From a new online retailer blowing away expectations in its first quarter since going public to the world's largest burger chain eating crow over its chicken wings, here's a rundown of the week's smartest moves and biggest blunders in the business world. Comcast (CMCSK), Netflix (NFLX), and You -- Winners (Mostly) The week kicked off with Netflix shelling out some dough to be able to stream its content faster for Comcast's Xfinity broadband subscribers. It's a move that's long overdue, as Netflix's monthly reports on different access providers showed that Xfinity speeds on Netflix video streams were starting to decline in recent months. This is the kind of stuff that would result in consumers either ditching Comcast or unsubscribing from Netflix so this "peering" arrangement benefits both companies. Naturally it's also good news for Comcast subscribers. No one likes to see online videos stop to buffer or degrade in image quality. Everybody wins -- mostly. (The down side, though, can be viewed like this: Netflix, the 800 lb. gorilla of streaming video, just caved on the net neutrality fight and agreed to pay for bandwidth. It'll have to pass that cost on to subscribers eventually. And with Netflix out of the fight, expect any smaller company that sees its content being throttled to pay the Danegeld quickly, too.) Sony (SNE) -- Loser The Japanese consumer electronics giant has been struggling on several fronts lately, and now it's retreating on the retail front, too. Sony revealed plans to close 20 of its 31 Sony Store locations in this country. The outcome probably won't come as a surprise to anyone that has walked by one of its locations. However, Sony's been scaling back through layoffs, selling off its Vaio computer business, and other acts of surrender. Keeping the Sony Store locations would just be a pu
Best Japanese Stocks To Invest In Right Now: NetSol Technologies Inc.(NTWK)
Netsol Technologies, Inc. designs, develops, and markets software products for the automobile finance and leasing, banking, healthcare, and financial services industries worldwide. It offers NetSol Financial Suite, which is an end-to-end solution that covers the leasing and finance cycle. The NetSol Financial Suite consist of software applications comprising Point of Sale, a front office processing system for the finance sector; Credit Application Processing System to handle the incoming credit applications from dealers, agents, brokers, and the direct sales force; Contract Management System to manage and maintain a contract; Wholesale Finance System to automate and manage the floor plan/bailment activities of dealerships; and Fleet Management System to handle fleet management needs. The NetSol Financial Suite also includes LeasePak that develops Web-enabled and Web-based tools for the leasing technology industry. In addition, the company offers LeaseSoft Portals and Modul es; enterprise wide information systems, such as LRMIS, MTMIS, and Hospital Management Systems; accounting outsourcing services; and career and technology programs. Further, it provides portfolio management systems for the financial services industry; and consulting, custom development, systems integration, and technical services for the healthcare, insurance, real estate, and technology markets. Additionally, the company offers business intelligence, independent system review, information security, and software process improvement consulting services; maintenance and support, and project management services; and solutions for the defense and military forces. It serves Fortune 500 manufacturers, automakers, financial institutions, utilities, technology providers, and government agencies. The company was formerly known as NetSol International, Inc. and changed its name to NetSol Technologies, Inc. in March 2002. NetSol Technologies, Inc. was founded in 1997 and is based in Ca labasas, California.
Advisors' Opinion:- [By CRWE]
NetSol Technologies (Nasdaq:NTWK), a provider of global IT and enterprise application solutions, reported that Mercedes-Benz Leasing Company Ltd. (China), went live with the NetSol Financial Suite (NFS(tm)).
Best Japanese Stocks To Invest In Right Now: ImmunoGen Inc.(IMGN)
ImmunoGen, Inc. engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload (TAP) technology. Its product candidates include Trastuzumab emtansine (T-DM1), a Phase III clinical trial product for HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product, which targets CD56 found on small-cell lung cancer, Merkel cell carcinoma, multiple myeloma, ovarian cancers, carcinoid tumors, and other cancers of neuroendocrine origin; IMGN529, a pre-investigational new drug stage drug for CD37+ B-cell malignancies, such as non-Hodgkin's lymphoma; and IMGN853, a preclinical stage product for cancers that overexpress folate receptor 1, including ovarian cancer. The company?s earlier-stage compounds in development stage comprise SAR3419, a Phase I clinical trial product for CD19+ B-cell malignancies, including non-Hodgkin's lymphoma; SAR650984, a Phase I clinical trial product for CD38+ hematological malignancies; SAR566658, a phase one clinical trial product for DS6+ solid tumors; and BT-062, a Phase I product for multiple myeloma. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Advisors' Opinion:- [By Sean Williams]
High-risk, high-reward suggestions
Exelixis (NASDAQ: EXEL ) : In November Exelixis had its first drug, known as Cometriq, approved by the Food and Drug Administration to treat metastatic medullary thyroid cancer. Although the market for this disease is pretty small -- somewhere between 500 and 700 people in the U.S. -- the near-tripling in progression-free survival, or PFS, in trials would indicate to me a strong likelihood that it could translate to success in other cancer types. In mid-stage prostate cancer trials, for instance, Cometriq was found to be particularly effective in dealing with bone metastases as a second or third-line treatment. We won't get any additional data until next year on Cometriq, but positive data on the prostate cancer front could be enough to double its share price if the PFS, compared to the placebo, is notably strong. ImmunoGen (NASDAQ: IMGN ) : In February, Roche�and ImmunoGen received approval for Kadcyla as a secondary treatment for HER2-positive breast cancer. This is ImmunoGen's first drug approval, and it gives the company a chance to showcase what I feel is one of the future pathways of fighting cancer -- its targeted-antibody payload, or TAP, technology. ImmunoGen's TAP technology works by attaching a toxin -- in this case Roche's Herceptin -- to an antibody, and teaching that antibody to release the to
There's an undeniably large dollar amount being pledged to cancer research, but, even if a drug gains approval, that's no guarantee that the biotech or pharmaceutical company behind that drug will be a success. Some of the biggest gains (and losses) come from taking a leap of faith based on clinical data, or the approval of one or two drugs or devices within a pipeline. After that, it's all up to the drug or devices' effectiveness, its pricing, and the success of the marketing teams promoting the drug or device. Here are a few high-risk, high-reward names you should be keeping your eye on. - [By John Udovich]
Cramer Talks Up Biotech and Cancer Biotech in Particular. For what his opinion might be worth, MSNBC�� Mad Money host Jim Cramer recently commented that the 25 best-performing small cap stocks this year are "almost entirely biotech." He went on to point out that Celldex Therapeutics has been "just incredible��and that other companies to watch include Celgene Corporation (NASDAQ: CELG), ImmunoGen, Inc (NASDAQ: IMGN) and Onyx Pharmaceuticals, Inc (NASDAQ: ONXX), which all have promising cancer products on the way. He also added that:�
- [By Sean Williams]
Now what: We're still in the top of the second inning of a nine-inning game here, but ADCs certainly appear to be the future of cancer therapy -- at least one path to treating it. Immunomedics still has a long road to climb as its two ADC peers are much further along in their development process. ImmunoGen (NASDAQ: IMGN ) , for instance, already has an FDA-approved drug for late-stage HER2-positive breast cancer known as Kadcyla that utilizes the company's proprietary targeted-antibody payload technology (the same concept as ADCs with a different name) in combination with Roche's�Herceptin. In trials, this combo extended median overall survival by 5.8 months over the placebo to 30.9 months. Something similar can be said for Seattle Genetics�and its ADC pipeline.
- [By Sean Williams]
A moat of competition, but plenty of upside
However, investors would probably be wise not to get too carried away with yesterday's news given that another therapy -- which I would certainly call revolutionary�-- known as Kadcyla for HER2-positive breast cancer was just approved in February. Kadcyla, developed by Roche�and ImmunoGen (NASDAQ: IMGN ) piggybacks a toxin on an antibody and, using ImmunoGen's proprietary targeted antibody payload technology, delivers a higher dose of toxin directly to the targeted cancer, which has a signature protein that causes the release of the toxin from the antibody. In late-stage trials, Kadcyla improved PFS by 50% over the placebo to 9.6 months.
No comments:
Post a Comment